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Abstract 
Background: The abuse of narcotic drugs and psychotropic substances such as amphetamines and ecstasy 
has had a growing trend. Tachycardia, increased blood pressure, hallucinations, panic attacks, and psychosis 
are the negative effects of methamphetamine abuse. The present study aimed to assess psychiatric disorders 
associated with methamphetamine-induced psychotic disorder. 
Methods: This cross-sectional study was performed from October 2013 to March 2014 on 165 patients 
hospitalized at Shahid Beheshti Hospital in Kerman, Iran, and diagnosed with psychosis induced by 
methamphetamine abuse within the previous 6 months. Study subjects were selected via census method. 
Based on the exclusion criteria and due to the lack of cooperation of some patients, 121 patients were enrolled 
in the study. Research data were gathered using clinical interviews, the Yale-Brown obsessive compulsive 
scale (Y-BOCS), Hamilton anxiety scale (HAM-A) and Hamilton rating scale for depression (HRSD), Young 
mania rating scale (YMRS), substance dependence severity scale (SDSS), positive and negative syndrome 
scale (PANSS), and clinical global impression (CGI) scale. The data analysis was performed using SPSS 
software, descriptive statistics, and ANOVA. 
Findings: Among the 121 patients of the sample group, 4 patients (3.3%) had anxiety, 58 patients (47.9%) 
depression, 30 patients (24.8%) obsessive-compulsive disorder (OCD), 20 patients (16.5%) bipolar mood 
disorder (BMD), 8 patients (6.6%) persistent psychotic symptoms, 85 patients (70.2%) personality disorder, 
and 36 patients (29.8%) had no personality disorders. The highest prevalence was related to borderline 
personality disorder (35.5%). However, 45 patients (37.2%) had no impairment associated with 
methamphetamine-induced psychosis. 
Conclusion: It seems that there is comorbidity between psychiatric disorders, including mood disorders, 
especially depressive disorder, childhood history of attention deficit hyperactivity disorder (ADHD), bipolar 
disorder, and personality disorders such as borderline personality disorder, and antisocial personality 
disorders, and methamphetamine abuse. 
Keywords: Methamphetamine, Depression, Anxiety, Obsessive-compulsive disorder, Manic disorder, 
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Introduction 
Methamphetamine or glass have amphetamine 
combinations and are a strong central nervous 
system stimulant with addictive properties. 
Currently, they are known as one of the most 
common illegal drugs in the world. According to 
an epidemiological study in America, the 
prevalence of this substance showed 59% increase 
between the years 1999 and 2002.1 Hitherto, no 
national study has been undertaken in Iran to 
assess the prevalence of methamphetamine 
dependence. However, a research on 2328 high 
school students in Lahijan, Iran, showed that 2.4% 
used methamphetamine; 56.3% had used it in the 
last month and 43.7% had used it in the last year.2  
In a study in Taiwan, the prevalence of major 
depression, alcohol abuse, pathological gambling, 
and antisocial personality disorder in 
methamphetamine dependent individuals were 
6.2, 20.9, 4.9, and 7.4 percentage respectively.3 In 
this study, 22.1% of subjects had 
methamphetamine-induced psychotic disorders.3 
In a comparative study in California, 170 
methamphetamine-dependent and 1410 non-
dependent prisoners were compared.4 The 
dependent prisoners had more symptoms of 
depression and suicidal thoughts in the previous 
12 months. This difference was still significant 
after controlling the confounding demographic 
factors and other drugs.4 In spite of the increasing 
prevalence of methamphetamine abuse, few 
studies have been conducted in Iran on the 
prevalence of psychiatric disorders associated 
with it. In a study on 26 methamphetamine 
dependent cases In Kermanshah, Iran, 25.0% of 
subjects had auditory or visual hallucinations, 
15.0% had phobias, 46.0% showed violent 
behavior, 27.6% had impaired concentration, and 
76.6% reported delusions and persecution.5  
In a survey on 500 consumers of ecstasy, it was 
proven that 16.0% of them experienced immediate 
anxiety followed by oral consumption of the 
drug.6 The survey revealed that 12.0% of the 
students suffered from anxiety or fear 24 hours 
after taking ecstasy.6 The results of several studies 
suggested that methamphetamine dependence 
had symptoms such as anxiety, confusion, 
insomnia, mood changes, and violent behavior.7-9 
It also caused the presentation of psychosis signs 
such as paranoia, auditory and visual 
hallucinations, and a tingling sensation under the 
skin.8,9  
In a study that was performed on 20 patients, 
it was found that 15.0% of them experienced a 
decrease in anxiety and 25.0% reported increased 
anxiety after taking ecstasy. In addition, it was 
reported that clinically some of the patients were 
feeling less anxious after two doses of 
methamphetamine.10 A cross-sectional study in 
Malaysia assessed the risk factors and factors 
associated with methamphetamine consumption 
in methamphetamine dependent patients and 
psychosis related to it. The results showed that of 
the 292 patients, 74.9% had a previous history of a 
psychiatric disorder and 13.0% had active 
psychiatric disorder. After analyzing the data, 
comorbidity of depressive disorder [Odds ratio 
(OR) = 7.18], bipolar disorder (OR = 13.81), and 
antisocial personality disorder (OR = 12.61) was 
manifested in the association with severe 
methamphetamine consumption and 
methamphetamine-induced psychosis. Depressive 
disorder and antisocial personality disorder were 
the only factors that were associated with current 
psychosis. The results also showed that 
methamphetamine dependence is not only 
associated with high risk of psychosis, but it is 
also associated with high risk of psychosis with 
comorbidity of mood disorders, antisocial 
personality disorder, and high consumption of 
methamphetamine.11 
This study aimed to review the possible role of 
concurrent psychiatric disorders (Axis I and II) in 
the development or exacerbation of 
methamphetamine dependence. Given that in 
Iran a large percentage of psychiatric hospital 
beds are occupied by patients with psychiatric 
problems, particularly methamphetamine-
induced psychosis, it was decided to study this 
group of patients, with the hope of finding a way 
to prevent and treat this problem. 
Methods 
This was a cross-sectional study. The study 
subjects were selected from among patients who 
were hospitalized at Shahid Beheshti Hospital in 
Kerman, Iran, and diagnosed with psychosis 
induced by methamphetamine abuse during a 
period of 6 months from October 2013 to March 
2014. Census sampling was performed on 165 
patients and included all patients who were 
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admitted with a diagnosis of psychosis induced 
by methamphetamine abuse. Of the 140 male 
patients, 5 patients due to personal satisfaction 
and being discharged from the hospital, 32 
patients due to unwillingness to continue the 
project, having tested positive for 
methamphetamine, or receiving electroconvulsive 
therapy (ECT) were excluded from the study. The 
study was conducted on 103 male patients. Of the 
25 hospitalized female patients, 2 patients due to 
personal satisfaction and being discharged from 
the hospital, and 5 patients due to unwillingness 
to continue the project or having tested positive 
for methamphetamine were excluded from the 
study. The study was conducted on 18 female 
patients. Finally, data analysis was performed on 
121 questionnaires. 
First, the patients were scored based on the 
clinical global impression (CGI) scale. The 
patients were examined twice a week or when 
their CGI score reached 2 or below 2 that 
indicated a normal state and that their psychotic 
signs were resolved (the average time was three 
weeks). The participants’ consent to participate in 
the research project was obtained, and they were 
provided with a detailed description of the project 
and the objectives of the study. In addition, an 
informed consent form was completed by the 
patients and their relatives. Then, they were 
provided with sufficient explanations, if they had 
the inclusion criteria. Subsequently, the 
participants were fully interviewed using 
structured psychiatric interviews. Moreover, any 
form of axis I and II psychiatric disorders were 
recorded in their research forms. This group was 
reinterviewed just before being discharged from 
the hospital, and psychiatric disorders related to 
each individual were reaffirmed using the 
abovementioned measures, such as the Hamilton 
rating scale for depression (HSRD), based on the 
diagnosis made and the severity of the disorder 
was evaluated. The results were recorded in each 
patient’s documents. These patients were 
reevaluated and their final research form was 
completed one month after admission and 
initiation of treatment. Psychotic symptoms 
persisted in some of the patients despite over a 
month of treatment and drug abuse withdrawal. 
Therefore, they were examined as stable 
psychosis. The exclusion criteria included 
concomitant use of cannabis or other psychoactive 
substances, serious health conditions such as 
seizures and mental retardation, and receiving 
ECT in the previous month. During the 
completion of the final research form, urinalysis 
test for methamphetamine was conducted to 
assure the lack of its use. Data collection tools 
consisted of 7 standard questionnaires.  
Yale-Brown obsessive compulsive scale (Y-BOCS) 
This inventory included 52 questions with 12 
aspects. Obsession was evaluated based on the 
following aspects: aggressive obsessions (9 items), 
contamination obsessions (9 items), physical 
obsession (2 items), washing and cleaning 
obsessions (4 questions), obsessive-compulsive 
disorder (OCD) and control obsessions (5 items), 
repeating and formalities obsessions (2 items), 
counting obsessions (2 items), sexual thoughts 
obsessions (4 questions), collecting and storing 
obsessions (1 items), religious thought obsessions 
(2 items), need for symmetry and precision 
obsessions (2 items), and miscellaneous thought 
obsessions (10 questions). The reliability and 
validity of this scale have been reported as 
suitable in many studies.12,13 The cut off point for 
this questionnaire was considered to be 16.14 In 
Iran, Cronbach's alpha reliability coefficient was 
estimated at 0.97 and test-retest correlation 
coefficients at 0.99. Construct validity was also 
reported as 0.84.15  
Hamilton anxiety scale (HAM-A) and Hamilton 
rating scale for depression (HRSD)  
The HAM-A and HSRD are 2 quantitative rating 
scales. It is designed in a way that the assessor 
rates anxiety and depression symptoms of the 
patients as quantity after clinical observations. 
The HSRD consists of 14 items. The cut off point 
for this questionnaire was considered to be 14.16 
Its correlation coefficient was 0.75 and reliability 
coefficient was 0.85 and its validity was reported 
as suitable.17,18 The HSRD consists of 21 items. The 
cut off point for this questionnaire was considered 
to be 7. A score below 7 illustrates no depression, 
score of 8 to 13 mild depression, score of 14 to 18 
moderate depression, score of 19 to 22 severe 
depression, and scores higher than 23 very severe 
depression.19 Its correlation coefficient was 0.65 
and reliability coefficient was 0.89, and the 
validity was reported as suitable.17-19 
Young mania rating scale (YMRS)  
The YMRS consists of 11 questions and is a 
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reliable measure with acceptable sensitivity and 
specificity. It has applications in clinical practice 
and research. The cut off point for this 
questionnaire was considered to be 5.16-20 
Concurrent validity of the YMRS with the 
International Comprehensive Diagnostic 
Questionnaire was equal to 0.87, and was 
estimated at 0.89 for the first evaluation and 0.84 
for the second evaluation.21,22  
Substance dependence severity scale (SDSS)  
The SDSS consisted of 5 questions which showed 
the severity of dependence on the drug. 
Hooshyari et al. reported a suitable reliability and 
validity for the questionnaire.22  
Positive and negative syndrome scale (PANSS)  
The PANSS is designed to assess symptoms and 
aspects of schizophrenia. It consists of 30 items, 
for the assessment of positive, negative, and other 
symptoms based on official clinical and semi-
structured interviews. The PANSS consists of 2 
parts as follows:  
1- Positive symptoms: 7 items (delusions, 
conceptual confusion, hallucinatory behavior, 
arousal, magnanimity, suspicion and 
mistrust/harm and injury, aggression) 
2- Negative symptoms: 7 items (affection, 
emotional isolation, poor relationships, passive 
social isolation or combined with indifference, 
difficulty in abstract thinking, lack of fluent and 
spontaneous conversation, stereotyped 
thinking) 
The validity and reliability of the scale was 
declared as suitable in numerous studies.23 In 
Iran, the questionnaire was standardized by 
Bakhshipour Roudsari and Dejkam.24 Its 
reliability for positive symptoms was 0.88 and for 
negative symptoms was 0.87 and for the entire 
test it was estimated as 0.87. The validity of the 
questionnaire, with some of the assessment tools 
that measured the structures associated with these 
emotions, was reported to be high.  
Clinical global index (CGI): The CGI is an  
8-item questionnaire used for the overall 
assessment of the clinical status of patients. It has 
two aspects of CGI-S and CGI-I. The former 
indicates the severity of illness and the latter 
measures the rate of recovery and response to 
treatment. It was important to identify the 
associated symptoms and reliability for CGI-S and 
CGI-I. The frequency of their occurrence had to be 
determined over the past 7 days. The intensity of 
the symptoms had to be determined. The effect of 
symptoms had to be indicated on a wide range of 
patient’s life circumstances which included work, 
home, school, and communication.25 This 
questionnaire was scored and classified based on 
a 7-point scale (1 indicated normal, not at all ill; 2 
borderline mentally ill; 3 mildly ill; 4 moderately 
ill; 5 markedly ill; 6 severely ill; and 7 extremely 
ill). In Iran, CGI has also been used by researches 
as a tool to assess the overall status of psychiatric 
patients and the results have been published in 
articles.25,26 The collected data were analyzed 
using SPSS software (version 21, SPSS Inc., 
Chicago, IL, USA), descriptive statistics, and 
ANOVA. 
Results 
The results indicated that among the 121 patients, 
who participated in the study, 18 patients (14.9%) 
were female and 103 patients (85.1%) were male. 
The highest percentage of education level was 
associated with secondary level education  
[31 patients (25.6%)] and diploma [24 patients 
(28.1%)]. Furthermore, 51 patients (42.0%) were 
married, 49 patients (40.5%) were single,  
12 patients (10.0%) were divorced or widowed, 
and 9 patients (7.5%) were living separately. 
Moreover, 77 patients (63.7%) were unemployed 
and 43 patients (35.6%) were full time or part time 
employees. The overall mean age of the 
participants was 32.54 ± 8.23 years.  
Based on the clinical interviews it was found 
that of the total 121 participants of the sample 
group, 4 patients (3.3%) had anxiety, 58 patients 
(47.9%) had depression, 30 patients (24.8%) had 
OCD, 20 patients (16.5%) had bipolar mood 
disorder (BMD), and 8 patients (6.6%) had stable 
psychotic symptoms. Among the studied patients,  
13 patients (10.7%) had mild depression, 16 
patients (13.2%) moderate depression, 12 (9.9%) 
severe depression, and 17 (14.0%) extremely 
severe depression. Moreover, 28 (23.1%) subjects 
had mild OCD, and 2 (1.7%) had severe OCD. The 
mean of each variable of the sample group is 
shown in table 1.  
Among the 121 patients of the sample group, 
85 patients (70.2%) had personality disorder and 
36 patients (29.8%) had no personality disorder. 
The highest prevalence was related to borderline 
personality (35.5%) (Table 2).  
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Table 1. Mean score of HAM-A and HRSD, Y-BOCS, YMRS, PANSS, and SDSS among respondents 
Variable  Mean ± SD Minimum Maximum 
Anxiety 22.0 ± 5.71 17 30 
Depression 18.8 ± 6.52 8 36 
Obsession 10.8 ± 3.90 0 20 
Mania 33.6 ± 8.22 18 45 
PANSS positive symptoms 17.7 ± 6.40 11 30 
PANSS negative symptoms 17.5 ± 7.29 6 24 
Severity of dependence 9.04 ± 2.52 4 19 
HAM-A: Hamilton anxiety scale; HRSD: Hamilton rating scale for depression ; Y-BOCS: Yale-Brown obsessive compulsive scale; 
YMRS: Young mania rating scale; PANSS: Positive and negative syndrome scale; SDSS: Substance dependence severity scale;  
SD: Standard deviation 
 
Based on the clinical interview and axis I, it 
was determined that among the 121 patients of 
the sample group 45 patients (37.2%) had 
methamphetamine-induced psychosis without 
any dysfunction (Table 3). ANOVA was used for 
the comparison of the severity of 
methamphetamine dependence among patients 
with depressive disorder, OCD, anxiety, and 
mania. The results showed that the differences 
between the severity of dependence among the 4 
groups was not statistically significant (P = 0.822). 
 
Table 2. Frequency and percentage of axis II 
personality disorders in the sample group  
Personality disorders n (%) 
Borderline personality 43 (35.5) 
Antisocial personality 8 (6.6) 
Borderline and antisocial personality 20 (16.5) 
Depressive personality 11 (9.1) 
Paranoid personality 1 (0.8) 
Dependent personality 1 (0.8) 
Dramatic personality 1 (0.8) 
Discussion 
In the present study, a total of 18 participants 
(14.9%) were female and 103 participants (85.1%) 
were male. Gender was suspected to be a risk 
factor for methamphetamine abuse. In individuals 
with lower education levels (61.2% were below 
diploma level), methamphetamine-induced 
psychosis was more frequent. With an increase in 
the education level, the amount of 
methamphetamine abuse had decreased. Perhaps 
this was due to the understanding and awareness 
of people regarding the dangers of substance 
abuse. Higher education level was a protective 
factor against methamphetamine abuse. In the 
present study, 42.0% were married and 58.0% were 
single or divorced. These figures were consistent 
with studies in Iran such as the study by Azizi  
et al.27 They noted that there is a growing rate of 
divorce among methamphetamine consumers and 
the present study confirmed this hypothesis. The 
results showed that 77 patients (63.7%) were 
unemployed. Being employed was a protective 
factor against methamphetamine abuse and being 
unemployed was strongly and significantly 
associated with methamphetamine abuse and was 
proposed as a risk factor. However, further studies 
are needed to determine the effects of 
methamphetamine abuse on occupation and 
whether methamphetamine use can increase the 
rate of unemployment. 
Of the 121 patients, 4 patients (3.2%) had 
anxiety disorder. This result was consistent with 
that of the study by Hatami et al. on the effects of 
methamphetamine on anxiety-related behavior in 
rats.28 Their study showed that the use of 
methamphetamine in a dose-dependent manner 
can lead to reduced anxiety in male rats.28 In 
addition, in the study by Martinez et al., 51.0% of 
the patients reported a reduction in anxiety and 
52.0% increase in anxiety after taking ecstasy.10 It 
was found that, clinically, after two doses of 
amphetamines, some people experience less 
anxiety.10 Among the participants in the study, 58 
patients (47.9%) had depressive disorder. This 
result was consistent with the results of a study on 
HIV patients and methamphetamine consumers.29 
Among this group, 95.0% reported that without the 
use of methamphetamine, they experienced 
depression, anxiety, and inability to enjoy 
pleasurable life activities.  
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Table 3. Frequency and percentage of axis I disorders in the sample group 
Associated disorders n (%) 
History of conduct disorder and oppositional defiant disorder  9 (7.4) 
Delusional disorder 2 (1.6) 
Anxiety disorder 4 (3.3) 
Depression 58 (47.9) 
BMD (mixed type I and II with psychotic features) 31 (25.6) 
PTSD 3 (2.5) 
OCD 30 (24.8) 
ADHD (lack of attention, impulsivity, composed) 22 (18.2) 
Schizophrenia 3 (2.5) 
Bereavement  2 (1.6) 
Psychotic 3 (2.5) 
People with underlying psychosis (delusions, schizophrenia, stable psychosis) 8 (6.6) 
Methamphetamine-induced psychosis without associated disorder 45 (37.2) 
BMD: Bipolar mood disorder; PTSD: Posttraumatic stress disorder; ADHD: Attention deficit hyperactivity disorder;  
OCD: Obsessive-compulsive disorder 
 
In a study on 1016 methamphetamine users 
undergoing outpatient treatment, the participants 
reported high levels of psychiatric symptoms, 
particularly depression, attempted suicide or 
suicidal thoughts, and anxiety.30 In a study in 
Quebec, Canada, on the relationship between 
depression and methamphetamine and ecstasy 
abuse in 3880 people, results showed that 
depressive symptoms were associated with the use 
of methamphetamine and ecstasy. In adolescents, 
methamphetamine and 3,4-methylenedioxy-
methamphetamine (MDMA) were independently 
associated with depressive symptoms.31 The study 
by Lecomte et al. also obtained results similar to 
that of the present study.32 Depressive disorders 
were the most important mood comorbidity 
among patients with methamphetamine abuse and 
could lead to methamphetamine-induced 
psychosis and hospitalization.  
In this study, there were 30 (24.8%) patients 
with OCD. In the review of literature, few studies 
were found regarding obsession, 
methamphetamine abuse, and methamphetamine-
induced psychosis. Nevertheless, the stereotypical 
movements arising from methamphetamine use 
which were mostly related to the field of anxiety 
disorders have been referred to. The questions 
regarding OCD symptoms and methamphetamine 
abuse, and whether this is a coincidence or there is 
a connection between these two require more 
extensive investigation and appropriate tools. In 
patients with OCD, comorbidities such as alcohol 
and substance abuse disorders, generalized anxiety 
disorder, and depressive disorders can be 
observed. However, in Iran, it seems that, due to 
the cultural and religious situation, there is less 
alcohol abuse disorder and instead problems 
associated with substance abuse, including 
methamphetamine, can be observed. 
The results of the present study showed that, of 
the 121 subjects studied, 20 (16.5%) had bipolar 
mood disorder. This finding was consistent with 
that of the study conducted in Malaysia.11 The 
study by Akindipe et al. was conducted in three 
rehabilitation institutes on 100 volunteers who had 
no physical or biological illnesses and were 
methamphetamine and drug addicts.33 The results 
showed that psychiatric disorders were found in 
36.0% of the subjects, including 17.0% mood 
disorders, 13.0% psychotic disorders, and 7% an 
anxiety disorder.33 This finding was consistent with 
the results of the present study. It appears that 
people with bipolar disorder were more at risk in 
the manic phase, which justifies this comorbidity in 
methamphetamine abusers. However, when the 
patient is in depressive phase, self-treatment and 
methamphetamine abuse, in order to cope with 
depression, are other possible reasons for the use 
of methamphetamine.  
According to the results, of the 121 patients 
studied, 8 patients over the course of a month of 
cessation of methamphetamine, despite being 
treated, had psychotic symptoms. Of this group of 
patients, 2 patients, according to their records, had 
hallucination disorder, 3 had schizophrenia, and 3 
had methamphetamine-induced stable psychosis. 
They were evaluated and their symptoms were 
measured according to the PANSS table. The 
Psychosis Caused by Methamphetamine and Comorbidities Eslami-Shahrbabaki et al. 
 
 
 
 
Addict Health, Winter & Spring 2015; Vol 7, No 1-2 43 
 
http://ahj.kmu.ac.ir,    4 April 
results revealed a significant difference between 
the positive and negative symptoms based on the 
PANSS score. The mean score in the positive 
symptoms group was 17.7 and in the negative 
symptoms group was 17.5. These findings were 
consistent with that of the study by Akindipe et al. 
that showed psychiatric disorders were found in 
36.0% of the subjects, mood disorders 16.0%, 
psychotic disorders 13.0%, and anxiety disorders 
7.0%, and independent prognostic factors 
including male gender (OR = 10.04, P = 0.004), 
being younger (OR = 0.87, P = 0.040), and having a 
previous psychiatric disorder (OR = 18.45,  
P < 0.001).33  
The lower rate of psychotic disorders (6.6%) in 
the patients of the present study suggested the 
limitation of the study group to those patients who 
had been hospitalized in this center due to the 
severity of their symptoms. In other words, these 
patients have the most severe and acute form of 
psychotic symptoms caused by methamphetamine 
abuse and the severity of their symptoms resulted 
in mandatory hospitalization. However, the study 
by Akindipe et al. was conducted on patients of 
outpatient drug rehabilitation centers who had not 
reached the hospitalization stage.33 Therefore, the 
statistical difference between the two studies can 
be justified.  
In this study, the frequency of axis II psychiatric 
disorders was also investigated. 85 patients (70.2%) 
had a disorder or a specific personality trait and 36 
patients (29.8%) had no personality disorder. 
Borderline personality disorder 35.5%, antisocial 
personality disorder 8.0% had the highest 
frequency, and 20 patients had both borderline and 
antisocial personality traits (16.5%). Depressive 
personality disorder was observed in 11 patients 
(9.1%), paranoid personality 1 person (0.8%), 
dependent character 1 person (0.8%), and dramatic 
character 1 person (0.8%). These figures were 
consistent with a study in Taiwan.3  
The rate of antisocial personality disorder 
among methamphetamine abusers was 4.7%. Social 
and cultural differences may be the reasons for 
these differences. These results confirmed those of 
the study conducted on 1016 methamphetamine 
users which showed high levels of anger control 
problems, violence, beatings, and use of firearms 
among these patients.30 On the other hand, in a 
study in Malaysia an association was observed 
between antisocial personality disorder  
(OR = 12.61) and severe methamphetamine 
consumption.11 The study results of Lecomte et al. 
suggested the existence of a relationship between 
psychotic disorder caused by prolonged and heavy 
methamphetamine abuse and antisocial 
personality disorder.32 In the present study, 
antisocial personality disorder has the second rank 
in terms of prevalence. This research with special 
circumstances has only been conducted in one 
hospital. Therefore, the actual statistics of patients 
with personality disorders, including antisocial 
personality disorder, who are often in prisons and 
penitentiaries were not included. It is suggested 
that future studies be conducted on all patients 
(those in prisons and penitentiaries). Thus, the 
ranking of personality disorders among 
methamphetamine abusers will differ.  
In this research the disorders or the history of 
axis I psychiatric disorders were studied. About 
63.0% of the patients in the study had an axis I 
psychiatric disorder. Most comorbidity of axis I 
was related to mood disorders including 
depression, OCD, and bipolar disorder. A 
significant percentage of patients (18.2%) had a 
history of attention deficit hyperactivity disorder 
(ADHD) during their childhood. In 37.2% of 
patients, methamphetamine-induced psychosis 
was not associated with other axis I psychiatric 
disorders. This finding was consistent with the 
study conducted in Taiwan, in terms of morbidity 
and not the prevalence rate.3 The difference in 
prevalence rate was due to the certain groups in 
this study.  
The results of this study were also consistent 
with a study conducted in California on the prison 
population, in terms of axis I disorders.4 The results 
were also consistent with that of the study by 
Mimiaga et al. on people with HIV.29 In addition, 
they were also consistent with a study on 1016 
outpatients regarding methamphetamine abuse.30 
The most similarity was found regarding the study 
method and patient selection between this study 
and the study conducted in Malaysia.11 The risk 
factors and factors related to methamphetamine 
abuse, methamphetamine dependent patients, and 
methamphetamine-induced psychosis were 
assessed. This study was conducted in a training 
hospital and a center for substance abuse. After 
analyzing the comorbidity data, depression  
(OR = 7.18), bipolar disorder (OR = 13.81), and 
antisocial personality disorder were the only factors 
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that were associated with current psychosis.11  
One important limitation of this study, which 
was also the strength of the project, was the limited 
number of studies similar to this design, both in 
Iran and in the world. This made the interpretation 
and comparison of the findings difficult. On the 
other hand, this was a good start for future 
research. According to these results, the researchers 
should plan for future studied with broader and 
more organized approach. Considering that the 
recent research was conducted on a specific group 
of patients with the most severe disorders 
(psychosis induced by methamphetamine) that 
caused hospitalization, therefore it only represented 
a small portion of the substance abusers and care 
must be taken in generalizing the results. 
Conclusion 
Psychiatric comorbidity including mood disorders, 
especially depression, history of ADHD in 
childhood, bipolar disorder and personality 
disorders including borderline and antisocial 
personality were important comorbidity in patients 
with methamphetamine abuse.11-34 
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